In contrast to the efficacy of HER2-targeted drugs against HER2+ breast cancer, the efficacy of fulvestrant against ER+ and/or PR+ MBC was limited to improvements in disease progression; fulvestrant as monotherapy improved median progression-free survival by approximately 3 months [11]. Here, ESR1 is linked to breast carcinoma.